World federation of societies of biological psychiatry guidelines for the pharmacological treatment of dementias in primary care

WFSBP Task Force on Mental Disorders in Primary Care, WFSBP Task Force on Dementia

Research output: Contribution to journalReview articlepeer-review

28 Citations (Scopus)


Objective. To define a practice guideline for biological treatment of dementias for general practitioners in primary care. Methods. TThis paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the Biological treatment of Alzheimer's disease and other dementias for treatment in primary care (Ihl et al. 2011). The recommendations were developed by a task force of international experts in the field and arc based on randomized controlled studies. Results. Anti-dementia medications neither cure, nor arrest, or alter the course of the disease. The type of dementia, the individual symptom constellation and the tolerability and evidence for efficacy should determine what medications should be used. In treating neuropsychiatrie symptoms, psychosocial intervention should be the treatment of first choice. For neuropsychiatrie symptoms, medications should only be considered when psychosocial interventions are not adequate and after cautious risk-benefit analysis. Conclusions. Depending on the diagnostic entity and clinical presentation different anti-dementia drugs can be recommended. These guidelines provide a practical approach for general practitioners managing dementias.

Original languageEnglish
Pages (from-to)2-7
Number of pages6
JournalInternational Journal of Psychiatry in Clinical Practice
Issue number1
Publication statusPublished - 2015 Mar 1
Externally publishedYes

Bibliographical note

Funding Information:
Lon Schneider has received grants from the NIH P50 AG05142, R01 AG033288, and R01 AG037561, the State of California, the Alzheimer’s Association for a registry for dementia and cognitive impairment trials and grant or research support from Baxter, Genentech, Johnson & Johnson, Eli Lilly, Novartis, and Pfizer. He discloses that within the last 3 years, he has served as a consultant for and received consulting fees from Abbvie Laboratories, AC Immune, Allon, AstraZeneca, Baxter, Biogen Idec, Biotie, Bristol-Myers Squibb, Elan, Eli Lilly, EnVivo, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Novartis, Piramal, Pfizer, Roche, Sanofi, Servier, Takeda, Tau Rx, Toyama, and Zinfandel; and in the past from Ipsen and Schwabe. Florence Thibaut has no conflict of interest to declare.

Publisher Copyright:
© 2015 Informa Healthcare.


  • Alzheimer's disease
  • Anti-dementia drugs
  • Dementia
  • Guidelines
  • Lewy body disease
  • Neuropsychiatric symptoms

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'World federation of societies of biological psychiatry guidelines for the pharmacological treatment of dementias in primary care'. Together they form a unique fingerprint.

Cite this